Blood Test for Early Diagnosis of Alzheimer’s Disease

1 Alzheimer’s disease (AD) is the most common cause of dementia [1]. The scientific literature offers a good description of the tissue changes in the brain resulting from Alzheimer’s disease. The prevalence of certain substances, biomarkers, in the cerebrospinal fluid reflects these changes. Alzheimer’s disease can be diagnosed by testing cerebrospinal fluid obtained by lumbar puncture (spinal tap). However, a blood test would be an easier way to diagnose the disease.

[1]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[2]  Susan M Resnick,et al.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.

[3]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[4]  Anders Wallin,et al.  Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment , 2010, Neurobiology of Aging.

[5]  P. Deyn,et al.  No correlation between time-linked plasma and CSF Aβ levels , 2009, Neurochemistry International.

[6]  L. Buée,et al.  Association of plasma amyloid β with risk of dementia , 2009, Neurology.

[7]  Fiona Crawford,et al.  Serum β-Amyloid Correlates with Neuropsychological Impairment , 2009, Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.

[8]  Daniel Paris,et al.  Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease. , 2008, Cytokine.

[9]  H. Fukuyama,et al.  Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.

[10]  J. Beijnen,et al.  Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-TOF MS). , 2008, Current clinical pharmacology.

[11]  G. Perry,et al.  Antigen–antibody dissociation in Alzheimer disease: a novel approach to diagnosis , 2008, Journal of neurochemistry.

[12]  J. Becker,et al.  Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study , 2008, Neurology.

[13]  M. Barcikowska,et al.  Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. , 2008, Neuro endocrinology letters.

[14]  B. Hyman,et al.  Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. , 2008, Archives of neurology.

[15]  Georg Kemmler,et al.  Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine , 2008, Neurobiology of Aging.

[16]  V. Mathura,et al.  The influence of diagnosis, intra- and inter-person variability on serum and plasma Aβ levels , 2007, Neuroscience Letters.

[17]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[18]  K. Blennow,et al.  Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies , 2007, Neurology.

[19]  I. Mook‐Jung,et al.  Serum Anti-Amyloid-β Antibodies and Alzheimer's Disease in Elderly Korean Patients , 2007, The Journal of international medical research.

[20]  O. Forlenza,et al.  Abnormal APP processing in platelets of patients with Alzheimer’s disease: correlations with membrane fluidity and cognitive decline , 2007, Psychopharmacology.

[21]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[22]  Henrik Zetterberg,et al.  Alzheimer's disease , 2006, The Lancet.

[23]  Zhikai Cao,et al.  Low Avidity and Level of Serum Anti-Aβ Antibodies in Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[24]  G. Ortiz,et al.  Altered β-Amyloid Precursor Protein Isoforms in Mexican Alzheimer’s Disease Patients , 2006, Disease markers.

[25]  B. Hyman,et al.  Autoantibodies to Redox-modified Oligomeric Aβ Are Attenuated in the Plasma of Alzheimer's Disease Patients* , 2005, Journal of Biological Chemistry.

[26]  H. Möller,et al.  Decreased serum amyloid β1–42 autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide , 2005, Biological Psychiatry.

[27]  E. Zamrini,et al.  Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides , 2004, Neurobiology of Aging.

[28]  A. Hofman,et al.  Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. , 2004, Archives of neurology.

[29]  S. Wisniewski,et al.  Plasma and cerebrospinal fluid α1‐antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment , 2003, Annals of neurology.

[30]  L. Rozzini,et al.  Early stages of probable Alzheimer disease are associated with changes in platelet amyloid precursor protein forms , 2002, Neurological Sciences.

[31]  N. Relkin,et al.  Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals , 2002, Experimental Gerontology.

[32]  G. Lenzi,et al.  Amyloid precursor protein in platelets , 2001, Neurology.

[33]  S. McIlroy,et al.  Association of serum AACT levels and AACT signal polymorphism with late‐onset Alzheimer's disease in Northern Ireland , 2000, International journal of geriatric psychiatry.

[34]  G. Annoni,et al.  Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? , 2000, Journal of Neuroimmunology.

[35]  L. Thal,et al.  Blood Levels of Alpha-1-Antichymotrypsin and Risk Factors for Alzheimer’s Disease: Effects of Gender and Apolipoprotein E Genotype , 2000, Dementia and Geriatric Cognitive Disorders.

[36]  E. Matsubara,et al.  Lipoprotein‐free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome , 1999, Annals of neurology.

[37]  L. Vignolo,et al.  Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. , 1998, Archives of neurology.

[38]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[39]  E. Porcellini,et al.  Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target. , 2008, Current pharmaceutical design.

[40]  R. Petersen,et al.  Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. , 2007, Archives of neurology.

[41]  T. J. Grabowski,et al.  Proteome-based plasma biomarkers for Alzheimer's disease , 2007 .

[42]  A. Hofman,et al.  Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. , 2006, The Lancet. Neurology.

[43]  I. Kloszewska,et al.  Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. , 2005, Acta neurobiologiae experimentalis.

[44]  J. Growdon,et al.  Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. , 2003, Archives of neurology.

[45]  L S Honig,et al.  Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. , 2003, Neurology.

[46]  C. Caltagirone,et al.  Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. , 2002, Archives of neurology.

[47]  H. Wiśniewski,et al.  Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .

[48]  G. Sanders,et al.  Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. , 1999, Genetic testing.

[49]  E. Oguni,et al.  Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. , 1996, Journal of the neurological sciences.

[50]  A. Kling,et al.  Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. , 1995, Neurobiology of aging.

[51]  H. Wiśniewski,et al.  Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. , 1994, Neurobiology of aging.